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Abstract
Background: A full-thickness macular hole (FTMH) is a common retinal condition associated with impaired
vision. Randomised controlled trials (RCTs) have demonstrated that surgery, by means of pars plana vitrectomy
and post-operative intraocular tamponade with gas, is effective for stage 2, 3 and 4 FTMH. Internal limiting
membrane (ILM) peeling has been introduced as an additional surgical manoeuvre to increase the success of the
surgery; i.e. increase rates of hole closure and visual improvement. However, little robust evidence exists
supporting the superiority of ILM peeling compared with no-peeling techniques. The purpose of FILMS (Full-
thickness macular hole and Internal Limiting Membrane peeling Study) is to determine whether ILM peeling
improves the visual function, the anatomical closure of FTMH, and the quality of life of patients affected by this
disorder, and the cost-effectiveness of the surgery.
Methods/Design: Patients with stage 2–3 idiopathic FTMH of less or equal than 18 months duration (based on
symptoms reported by the participant) and with a visual acuity ≤ 20/40 in the study eye will be enrolled in this
FILMS from eight sites across the UK and Ireland. Participants will be randomised to receive combined cataract
surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative
intraocular tamponade with gas, with or without ILM peeling. The primary outcome is distance visual acuity at 6
months. Secondary outcomes include distance visual acuity at 3 and 24 months, near visual acuity at 3, 6, and 24
months, contrast sensitivity at 6 months, reading speed at 6 months, anatomical closure of the macular hole at
each time point (1, 3, 6, and 24 months), health related quality of life (HRQOL) at six months, costs to the health
service and the participant, incremental costs per quality adjusted life year (QALY) and adverse events.
Discussion: FILMS will provide high quality evidence on the role of ILM peeling in FTMH surgery.
Trial registration: This trial is registered with Current Controlled Trials ISRCTN number 33175422 and
Clinical Trials.gov identifier NCT00286507.
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An idiopathic full-thickness macular hole (FTMH) repre-
sents a defect in the area of maximal vision of the retina,
the fovea. If left untreated, FTMH usually leads to severe
visual impairment, with over a third of patients experienc-
ing a drop in vision to levels of 20/200 or worse [1].
FTMH are common. The incidence has not been reported
in the UK but it is estimated to be around 3/10,000/year
based on reported incidence in a similar population in the
USA [2]. Macular hole surgery represents one of the most
common procedures performed by vitreo-retinal surgeons
[3].
Four stages (1–4) of FTMH have been described, often
with increasing severity of visual loss as the stage of the
hole progresses [4]. Around 40% of cases are likely to
progress beyond stage 1 [5,6]. Up to 20% of affected peo-
ple will develop a FTMH in both eyes [7].
Randomised controlled clinical trials conducted in the
1990s showed that surgery was effective for stage 2, 3 and
4 FTMH [8,9]. Several observational studies have sug-
gested that peeling the internal limiting membrane (ILM)
of the retina may improve the visual and anatomical suc-
cess of the surgery (reviewed by Abdelkader and Lois)
[10,11]. However, it is difficult to interpret the results of
these studies and compare them with those from other
series in which the ILM was not peeled since parameters
which are likely to influence anatomical and visual out-
comes, including stage of the hole, pre-operative vision,
duration of symptoms, size of the macular hole, presence
of cataract, and extent of ILM peeling varied among study
populations.
Recently, data from two randomised controlled trials
(RCT) evaluating the effect of ILM peeling in macular hole
surgery have become available [12] (La Cour M, Personal
communication, Combined meeting of the Club Jules
Gonin and the Retina Society, Cape Town, October 15–
20, 2006). Kwok and collaborators reported statistically
significantly higher rates of macular hole closure and vis-
ual acuity improvement following ILM peeling compared
with a no-peeling technique in an RCT involving 49 par-
ticipants (51 eyes) with stage 2, 3 and 4 FTMH [12]. A
high proportion of patients in this RCT had FTMH on
stage 4 (50% and 32% in the ILM peel and no ILM peel
group, respectively) and few had FTMH on stage 2 (15.4%
and 12% in the ILM peel and no ILM-peel groups, respec-
tively). The timing of final outcome assessment was vari-
able, ranging from 6–23 months. La Cour and associates
(La Cour M, Personal communication, Combined meet-
ing of the Club Jules Gonin and the Retina Society, Cape
Town, October 15–20, 2006) also found a higher rate of
macular hole closure following ILM peeling in an interim
analysis of an RCT when only 22 patients were enrolled.
Based on these results, further recruitment for this RCT
has been halted. Another RCT evaluating the effect of ILM
peeling in macular hole surgery in patients with large idi-
opathic macular holes (>400 microns) is currently under-
way http://clinicaltrial.gov/ct/gui, with a recruitment
target of 80 patients.
Peeling the ILM is a surgical technique that can be techni-
cally challenging, even for experienced vitreo-retinal sur-
geons, unless a dye is used to stain the ILM. Indocyanine
green has been used for several years to facilitate the visu-
alisation and removal of the ILM during macular hole sur-
gery. However, recent research suggests that Indocyanine
green may be toxic to retinal pigment epithelium (RPE)
and ganglion cells, and concerns now exist regarding its
used for this purpose (revised by Abdelkader and Lois)
[10,13]. New dyes have been introduced, including Infra-
cyanine Green [14] Trypan blue [15]. Although long-term
data is still needed, these latter dyes seem to be safe and
appear to be a good alternative to Indocyanine Green
[10].
Some concerns have been raised with regards to the possi-
ble damaging effect of ILM peeling in the nerve fibre layer
of the retina, which potentially could have adverse effects
on central vision [16,17]. There is uncertainty in the liter-
ature and among vitreo-retinal surgeons about the bal-
ance of potential benefits and adverse effects of ILM
peeling in FTMH surgery for stage 2–3 holes. Some sur-
geons prefer to perform ILM peeling in all cases, whereas
others reserve ILM peeling to treat large and/or long-
standing macular holes. An Ophthalmology Technology
Assessment reviewed the efficacy and safety of macular
hole surgery [18] concluded that further research was
needed to address whether ILM peeling offered surgical
and functional benefit to patients with FTMH.
The hypothesis tested in FILMS is that ILM peeling is supe-
rior to the non-peeling procedure with regards to improv-
ing vision and quality of life, achieving macular hole
closure and that is cost effective.
Methods and design
1. Trial recruitment
Participants will be identified in general and specialised
ophthalmic clinics of all eight hospitals participating in
this trial: Aberdeen and Dundee (Scotland); Bristol, Sun-
derland, Oxford, Liverpool, (England); Dublin and
Waterford (Ireland).
1.1. Inclusion and exclusion criteria
Eligible participants are those with idiopathic FTMH in
stages 2–3, of less or equal than 18 months duration
(based on symptoms reported by the patient) and with a
visual acuity equal to or worse than 20/40 in the studyPage 2 of 8
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most recent onset of visual loss will be randomised for the
study. Individuals with FTMH in stages 1 and 4, those
with idiopathic FTMH stages 2–3 but longer than 18
months duration or with other causes of decreased vision
(e.g. corneal scarring, age-related macular degeneration,
diabetic retinopathy, glaucoma if central and/or paracen-
tral absolute visual field defects are present) and those
with FTMH related to high myopia (> 6 dioptres) or
trauma will be excluded from the study. Individuals that
do not understand English and those unable to give
informed consent will not be included.
1.2. Informing potential participants about the trial
The local clinical investigator (consultant vitreo-retinal
surgeon or a doctor/nurse/optometrist working with the
consultant) will describe the study face-to-face to poten-
tially eligible participants. Verbal information will be sup-
ported by a patient information leaflet containing
information about macular holes and current surgical
treatments.
1.3. Consent to participate
Once eligibility has been confirmed, the local clinical
investigator will ask if the potential participant is inter-
ested in joining the trial. If so, the participant will be given
a consent form. After checking with the participant that
the consent form is understood, the consultant vitreo-ret-
inal surgeon will invite the participant to sign the form
and will countersign it. One copy of the consent form will
be given to the patient, another will be filed in the hospi-
tal case notes, and the third will be kept at the Trial Office
(Centre for Healthcare Randomised Trials (CHaRT),
Health Services Research Unit, University of Aberdeen,
Scotland).
1.4 Information collected at trial entry
Once a participant agrees to join the trial, research optom-
etrists and vitreo-retinal surgeons at each centre will
record baseline data on FILMS case report forms (CRF)
including full name, address and telephone number, date
of birth, gender, hospital number and general practi-
tioner's contact details, and check that eligibility criteria
are met prior to enrolment on the study. CRFs are con-
tained in booklets (one booklet per participant recruited),
with triplicates of each visit CRF (one to keep in the book-
let, one to file in the patient's medical records and one to
be sent to the Trial Office) with the exception of the surgi-
cal CRF (see below) for which there are only two copies
(one for the surgeon and one to be sent by the surgeon to
the Trial Office to maintain masking of the participant
and optometrist) in each booklet. Some demographic
data (gender), the date of attempted recruitment, the cen-
tre, and the grounds for non-inclusion will be collected
also on ineligible and unwilling participants as well as on
participants not recruited for other reasons.
Within 2 weeks (± 2 weeks) prior to the date scheduled for
the surgery baseline data on primary and secondary out-
comes studied (Table 1) will be collected and recorded on
the appropriate CRF for each participant. In addition,
information on duration of symptoms related to the mac-
ular hole and lens status (phakic, pseudophakic or apha-
kic) and lens grading in phakic eyes, based on the Age
Related Eye Disease Study (AREDS) classification, will be
also collected [19].
2. Trial interventions
All surgeries will be performed by a consultant vitreo-ret-
inal surgeon or by an experienced vitreo-retinal fellow,
supervised by the consultant vitreo-retinal surgeon. All
phakic participants will undergo cataract extraction by
means of phacoemulsification and intraocular lens
implantation at the time of the macular hole surgery.
Participants will be randomised to receive macular hole
surgery either with ILM peeling or without ILM peeling. In
participants not receiving ILM peeling, a pars plana vitrec-
tomy will be performed, including detachment and
removal of the posterior hyaloid, followed by a fluid-air
exchange and air-gas (12% C3F8) exchange. In partici-
pants undergoing ILM peeling, a pars plana vitrectomy,
including detachment and removal of the posterior
hyaloid, will be similarly performed but, in addition, fol-
lowing ILM staining with Trypan blue (Membrane Blue,
DORC) the ILM will be peeled off the retina, in an area of
around 1–2 disc diameters around the hole. If staining of
the ILM is considered inadequate, re-staining is permitted.
The surgery will be completed by a fluid-air exchange and
an air-gas (12% C3F8) exchange. Details of the surgery will
be recorded in the appropriate case report form. To assure
masking of the optometrists and participants (see below)
to the allocated treatment, once the CRF for the surgery is
filled one copy will be removed from the CRF booklet and
kept locked by the vitreo-retinal surgeon and the other
will be sent immediately to the Trials Office.
The surgical CRF contains information on date of admis-
sion; grade of the surgeon, assistant surgeon and anaes-
thetist [consultant, staff grade or associate specialist (non-
training posts) or registrar or senior house officer (train-
ing posts)]; type of anaesthesia; performance or lack of
performance of ILM peeling around the hole and the
degree of completeness of this manoeuvre (peel complete
or incomplete); confirmation that the vitreous was
attached at the time of the surgery and any complications
occurring intraoperatively. In addition, the time at which
the participant enters the anaesthetic room, the "operat-
ing time", defined as the time between starting the casePage 3 of 8
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eye, ready for the surgery) and completing the case (mov-
ing the microscope away from the participant's eye at the
end of the procedure), and the time at which the partici-
pant leaves the theatre (or the recovery room when appro-
priate) will be recorded. The date of discharge from the
hospital will also be recorded.
All participants will be instructed to posture face down as
soon as possible after the surgery for 45 minutes every
hour for a period of 5–7 days. Each participant will be
given a posturing chart to record the time postured during
these 5–7 days, which will be sent, once filled, to the cen-
tral Trials office in Aberdeen. In addition, at the 1 month
follow-up visit the participant will be asked how many
days in total did they posture following surgery (in case
they have not completed and returned the posturing
chart).
3. Treatment allocation
The existing central randomisation service (fully auto-
mated telephone randomisation) in the Centre for
Healthcare Randomised Trials (CHaRT), Health Services
Research Unit at the University of Aberdeen, will be used
to randomise participants. A minimisation algorithm
(according to Taves, with p = 1)20, considering trial centre,
distance visual acuity in the study eye and in the fellow
eye (20/40–20/160; 20/200–20/500; <20/500), duration
of the macular hole (= 1 year; > 1 year), lens status (pha-
kic;aphakic;pseudophakic) and stage of the hole (Grade 2;
Grade 3), as classified by the vitreo-retinal surgeon will be
used.
4. Masking of intervention and outcome assessment
Patients, optometrists obtaining data on visual function,
photographers and the observer at the University of Aber-
deen responsible for analysing the size and status of the
hole will be masked with regards to the type of procedure
performed to the participant and will remain masked
throughout the study. Only the vitreo-retinal surgeon, for
Table 1: Summary of outcome measures, tools used to obtain them, and eye in which they were assessed at baseline and at each 
follow-up visit
Outcome measure Tool Eye Baseline 1 month 3 months 6 months 24 months
Distance VA ETDRS charts Study eye
Contralateral eye
X
X
X
X
X
X
X
X
Near VA Bailey-Lovie charts Study eye
Contralateral eye
X
X
X
X
X
X
X
X
Contrast sensitivity Pelli-Robson chart Study eye
Contralateral eye
X
X
X
X
Reading speed MN Read chart Study eye
Contralateral eye
X
X
X
X
Stage of FTMH• Slit-lamp biomicroscopy Study eye X
Status of FTMH Slit-lamp biomicroscopy+
Colour and red free photographs#
Study eye
Study eye
X
X
X
X
X
X
X
X
X
X
HRQoL NEI-VFQ-25 and EQ-5D 
questionnaires
N/A X X X
Costs:
- Primary care Health Service
Utilisation questionnaire
N/A X
- Secondary care Targeted questions in CRF N/A X X X
- Participants Participant Unit Cost questionnaire N/A X
VA = visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study visual acuity charts; FTMH = full-thickness macular hole; HRQoL = health 
related quality of life; N/A = not applicable; • = Stage 2: absence of posterior vitreous detachment and whenever the largest diameter of the hole is 
≤ 400 microns; Stage 3: absence of posterior hyaloid separation but when the largest diameter of the hole is > 400 microns, as classified by the 
vitreo-retinal surgeon; + = closed, open with subretinal fluid around it or open with no subretinal fluid around it as determined by the vitreo-retinal 
surgeon; # = size of the macular hole and status of the macular hole (closed, open with subretinal fluid around it or open with no subretinal fluid 
around it) as determined by a masked observer at the University of Aberdeen.Page 4 of 8
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performed.
At enrolment potential participants will be informed that
they will be unaware as to whether they had received
internal limiting membrane peeling at the time of the
macular hole surgery. The surgeons will know which type
of procedure they have performed but they will not reveal
this to participants. The only scenario in which the partic-
ipant will be unmasked is if the macular hole is not closed
following surgery. In this situation, the participant will be
offered further surgery and the nature of this surgery will
be discussed with the participant.
5. Subsequent arrangements
5. 1. Informing the general practitioner
Following formal trial entry, the sites will contact the gen-
eral practitioner through the post to let him/her know
about the participant's involvement in the trial. The letter
sent to the general practitioner includes a brief description
of the trial together with a request to notify the Trial Office
if any events that may lead to their patient failing to attend
any of the follow-up visits.
5. 2. Follow-up
Participants will be followed at 1, 3, 6 and 24 months post
surgery. Visits will take place within 2 weeks from the
scheduled date. All data will be recorded at each visit in
the appropriate CRF. Table 1 summarises the data col-
lected at each of the follow-up visits. Post-operative com-
plications will also be recorded at each visit.
6. Data processing
Data from the various sources outlined above will be sent
to the Trial Office in Aberdeen for processing. A random
10% sample of that data will be double checked for accu-
racy. Staff in Aberdeen will work closely with investigators
at all participating sites to ensure complete and accurate
data recording. Extensive range checks will be conducted
to further enhance the quality of the data.
7. Outcome assessment
The primary outcome of the study is the mean difference
between treatment groups in the Early Treatment Diabetic
Retinopathy Study (ETDRS) distance visual acuity score at
6 months.
Secondary outcomes include ETDRS distance visual acuity
at 3 and 24 months, near visual acuity at 3, 6 and 24
months, contrast sensitivity at 6 months, reading speed at
6 months, anatomical closure of the macular hole at each
time point (1, 3, 6 and 24 months), health related quality
of life (HRQOL) at 6 months, costs to the health service
and the participant, incremental costs per QALY and
adverse events.
A summary of the outcome measures studied and the
tools used for their assessment at baseline and at each fol-
low-up visit is provided in Table 1.
8. Analysis of the data
8.1. Statistical analysis
The principal analysis will take place when six month data
collection is complete. A subsequent analysis will be con-
ducted once 24 months data is available. The statistical
analysis will be based on all patients as randomised, irre-
spective of subsequent treatment received and, thus, will
follow the intention to treat principle. Additionally, the
primary analysis will be based upon available case data
with no imputation of missing values. Sensitivity analy-
ses, which impute extreme values will be performed for
the primary outcome (visual acuity at 6 months) and for
other visual function and quality of life secondary out-
comes as appropriate. Statistical significance for the pri-
mary and secondary outcomes will be based on two-sided
tests with 2P ≤ 0.05 taken as the criterion for statistical sig-
nificance. The primary outcome of ETDRS visual acuity
score at 6 months will be compared between the two
groups (ILM peel and no ILM peel) using a generalised
linear model to calculate the mean difference adjusted for
the baseline score and minimisation covariates. The pri-
mary outcome will additionally be analysed according to
the pre-specified subgroups (see Treatment Allocation sec-
tion, minimisation criteria, above) by including corre-
sponding interaction term(s) in the regression model. For
these subgroup analyses, stricter criteria for statistical sig-
nificance (2P ≤ 0.01) will be applied. Secondary out-
comes, adverse events and re-operation rates will be
analysed using generalised linear model with adjustment
for minimisation covariates as appropriate. Analyses of
health related quality of life measures (EQ-5D and VFQ-
25) and secondary measures of visual function (contrast
sensitivity, MN Reading speed and distance and near vis-
ual acuity) will be adjusted for the corresponding baseline
score in addition to the minimisation variables.
8.4 Economic analysis
8.4.1 Estimation of costs
Costs that fall on both the participant and the health serv-
ice will be elicited. Participant costs will comprise three
main elements: self purchased healthcare; travel costs for
making return visit(s) to NHS health care; and time costs
of travelling and attending NHS health care.
Self-purchased health care will include items such as pre-
scription costs and over the counter medications. Infor-
mation about these will be collected in the Participant
Unit Cost questionnaire, which will be sent by post to
each participant prior to the 6-month visit, and which will
be returned, once filled by the participant, to the central
office in Aberdeen. Estimation of travel costs requiresPage 5 of 8
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to their general practitioner, ophthalmologist or optome-
trists and the unit cost of making a return journey to each
type of health care provider. The cost of participant time
will be estimated in a similar manner. The participant will
be asked, in the Participant Unit Cost Questionnaire, how
long they spent travelling to and attending their last visit
to each type of health care provider. Participants will be
asked also what activity they would have been undertak-
ing (e.g. paid work, leisure, housework) had they not
attended the health care provider. These data will be pre-
sented in their natural units, e.g. hours, and also costed
using standard economic conventions, e.g. the Depart-
ment of Transport estimates for the value of leisure time.
These unit time costs, measured in terms of their natural
and monetary terms, will then be combined with esti-
mates of number of health care contacts derived from the
health care utilisation questions.
Health service costs of surgery will be recorded prospec-
tively for every participant in the study. Main areas of costs
are operation costs include staff, consumables, capital and
overheads.
Use of secondary care services following the operation
will be collected on the 3, 6 and 24 month CRFs. Informa-
tion on non-protocol (protocol visits are those scheduled
for the purposes of data collection) eye-related visit(s) to
the outpatients/casualty department or hospital admis-
sion(s) and need for further surgery(ies) will be also col-
lected.
Use of primary care services such as prescription medica-
tions, contacts with primary care practitioners e.g. general
practitioners, practice nurses, optometrists and ophthal-
mologists will be collected via the Health Care Unit Cost
questionnaire administered at 6 months follow-up.
8.4.2 Estimation of effectiveness
In the economic analysis effectiveness at 6 and 24 months
will be measured in terms of quality adjusted life years
(QALYs). QALYs will be estimated by the participants'
responses to the EQ-5D questionnaire (administered at
baseline, 6 and 24 months). The estimation of QALYs will
take account of the mortality of study participants. Partic-
ipants who die within the study follow-up will be
assigned a zero utility weight from their death until the
end of the study follow up. QALYs before death will be
estimated using linear extrapolation between the QALY
scores at baseline and all available EQ-5D scores up to
death or the end of the study follow-up. The method of
eliciting QALYs described is one commonly adopted in
economic evaluation [21].
8.4.3 Estimation of cost-effectiveness
The primary analysis will be based on six-month follow-
up of the trial for the incremental cost per QALY. A second
analysis will be conducted for a 24-month time horizon
using the same methods as outlined in this manuscript.
The results will be presented as point estimates of mean
incremental costs, QALYs, and incremental cost per
QALY. Measures of variance for these outcomes are likely
to involve bootstrapping estimates of costs, QALYs, and
incremental cost per QALY. Incremental cost-effectiveness
data will be presented in terms of cost-effectiveness
acceptability curves (CEACs).
Other forms of uncertainty, e.g. concerning the unit cost
of a resource from the different centres, will be addressed
using standard deterministic sensitivity analysis. Where
feasible the results of the sensitivity analyses will also be
presented as CEACs.
A secondary economic analysis will be presented. In this
analysis the costs and consequences measured in terms of
visual function and adverse events will be presented as a
cost-consequence analysis. Where appropriate uncertainty
will be explored using similar approaches to those out-
lines above.
9. Sample size
It was estimated that sixty-four participants will be
required in each group, assuming a common standard
deviation of 12 ETDRS points in these two randomised
groups, to detect a 6 ETDRS score difference (an effect size
of 0.5) using a two sample two sided t-test at a 5% level of
significance and 80% power (128 patients). This calcula-
tion was based on estimated mean post treatment EDTRS
visual acuity scores and the corresponding SDs for each
intervention arm from published studies of alternative
interventions for macular hole surgery [22,23]. To allow
for a loss to follow up of 10% we aim to recruit a total of
140 participants into the trial.
For the subgroup analysis of stage, if 70% of the partici-
pants are recruited with the more severe stage 3 macular
holes, the study will have 80% power to detect an effect
size of 0.6. If a common standard deviation of 12 points
is assumed, there will be sufficient power to detect a mean
difference of 7 EDTRS letters between the randomised
groups.
10. Organisation
10.1 Local organisation
Each collaborating centre will identify a clinical co-ordina-
tor. The responsibilities of this person will be to 1) estab-
lish the trial locally, 2) take responsibility for clinical
aspects of the trial locally (for example, if any particular
concerns emerge), 3) notify the Trial Office of any sus-Page 6 of 8
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related to trial participation, 4) ensure masking of the
optometrist and participant to the allocated surgery.
Each participating centre will appoint a study optometrist
to co-ordinate the day-to-day aspects of the trial. The
responsibilities of this person are 1) to conduct visual
assessment of the participants involved in the trial, 2) tel-
ephone the Trial Office to obtain randomisation and allo-
cate treatment for participants enrolled in the study, and
to let the vitreo-retinal surgeon know about it before the
surgery, 3) arrange follow-up appointments, 4) keep reg-
ular contact with the local clinical co-ordinator, with noti-
fication of any problem or unexpected development, 5)
maintain regular contact with the Trial Office, 6) provide
information about the trial to the participants, 7) ensure
CRFs are completed and sent to the Trial Office, 8) ensure
that enrolled participants will undergo macular hole sur-
gery within 2 weeks from the baseline assessment, 9) be
masked to the allocated treatment, and 10) clarify the sit-
uation when the Trial Office fails to make a contact with a
local participant, getting in touch by phone or a visit, if
necessary.
10. 2 Trial co-ordination
10. 2. 1. The Trial Office
The Trial Office at the Centre for Healthcare Randomised
Trials (CHaRT), at the Health Services Research Unit, Uni-
versity of Aberdeen, will provide the day-to-day support to
the clinical centres. CHaRT will be responsible for collec-
tion of data (in collaboration with the local study optom-
etrists), data processing and analysis. It will be responsible
for randomisation, distribution and collation of CRFs and
questionnaires.
10. 2. 2. The Project Management Group
The day to day running of the trial will be co-ordinated by
its Project Management Group. This consists of the chief
investigator Noemi Lois, together with Jennifer Burr, John
Norrie, Luke Vale, Jonathan Cook, Alison McDonald, Gla-
dys McPherson, Charles Boachie and Laura Ternent.
10.3 Data and safety monitoring
10. 3. 1. The Data Monitoring Committee
The data monitoring committee (DMC) will comprise of
a statistician, Prof. Gordon Murray (chair) and by two vit-
reo-retinal surgeons, Mr William Aylward and Mr Tom
Williamson.
10. 3. 2. Other safety concerns
Collaborators and participants can contact the trial office
or the chief investigator about any worries they may have
about the trial.
FILMS will be conducted according to the MRC Good
Clinical Practice Guidelines (1998) and the Data Protec-
tion Act (1998). Approval of The Multicentre Research
Ethics Committee, the Local Ethics Committees and local
hospital trusts of each participating centre has been
obtained.
Publication
The success of the trial depends entirely on the collabora-
tion of a large number of participants, and a group of Vit-
reo-Retinal surgeons and optometrists. For this reason,
chief credit for the trial will be given, not to the commit-
tees or central organisers, but to all those who have collab-
orated in the trial (the FILMS Study Group). The trial's
publication policy is described in detail in the Site File and
follows the rules of the International Committee of Med-
ical Journal Editors. The results of the trial will be reported
first to trial collaborators. The main report will be drafted
by the Project Management Group, and circulated to all
clinical co-ordinators and members of the DMC for com-
ments. The final version will be agreed by all before sub-
mission for publication, on behalf of the collaboration.
To safeguard the integrity of the main trial, reports of
explanatory or satellite studies would not be submitted
for publication without prior discussion with the Project
Management Group.
Once the main report has been published, a summary will
be sent to the GP of participants involved in the trial and
to individual participants' or relatives' who had indicated
they would wish to receive one.
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